Hematologic malignancies
Cellectis focuses on clinical research in aggressive blood cancers, with activity centered on relapsed and refractory disease. The sponsor’s studies address B-cell acute lymphoblastic leukemia and B-cell non-Hodgkin lymphoma, reflecting a therapeutic interest in difficult-to-treat malignancies of the lymphoid system.
- B-cell acute lymphoblastic leukemia
- B-cell non-Hodgkin lymphoma
- Large B-cell lymphoma
The clinical program includes patients whose disease has persisted after prior treatment, including those with prior CD19-directed therapy.
Cell-based immunotherapy
The sponsor’s research landscape is built around allogeneic CAR T-cell therapy for B-cell malignancies. Its funded trials examine engineered T-cell approaches designed to target malignant B cells in settings where standard treatment options have been limited.
- UCART22
- UCART20x22
- Engineered T-cell therapy
These studies are directed toward identifying suitable treatment options for relapsed or refractory disease across multiple B-cell cancer subtypes.
CD22-targeted treatment
Cellectis is actively involved in research on CD22-directed immunotherapy for B-cell acute lymphoblastic leukemia. This area of interest reflects a focus on antigen-targeted treatment strategies in patients with persistent disease after earlier therapy.
- CD22 antigen targeting
- R/R B-ALL
- Post-CD19 therapy disease
The program includes efforts to define treatment suitability in patients with refractory leukemia who have limited remaining options.
Dual-target B-cell therapy
The sponsor also supports research in dual-antigen targeting for B-cell lymphoma, with attention to tumors expressing overlapping B-cell markers. This area includes studies in mature B-cell non-Hodgkin lymphoma and large B-cell lymphoma.
- Dual CD20 and CD22 targeting
- Mature B-cell non-Hodgkin lymphoma
- Large B-cell lymphoma
Its clinical interest extends to patients with refractory lymphoma requiring new immunotherapy options.
